NCT06367153

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

The Effect of Multiple Doses of BI 1569912 on the Single-dose Pharmacokinetics of Repaglinide, Midazolam and Bupropion Following Oral Administration in Healthy Male and Female Subjects (an Open-label, 2-period Fixed-sequence Trial)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main objective of this trial is to investigate the effect of multiple oral doses of BI 1569912 on the pharmacokinetics of a single oral dose of repaglinide, midazolam and bupropion (i.e. sensitive CYP2C8, CYP3A4 and CYP2B6 substrates).

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BI 1569912	BI 1569912
DRUG	repaglinide	repaglinide
DRUG	midazolam	midazolam
DRUG	bupropion	bupropion

Timeline

• Start date: 2024-05-15
• Primary completion: 2024-08-20
• Completion: 2024-08-20
• First posted: 2024-04-16
• Last updated: 2024-11-13

Locations

1 site across 1 country: Belgium